BioMark Diagnostics (CSE: BUX; FSE: 20B; OTCQB: BMKDF) has announced that the peer-reviewed journal Frontiers in Oncology has accepted for publication the company’s research on a machine learning (ML) predictive model for lung cancer detection.
According to BioMark, the accepted article, titled Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolic biomarkers for lung cancer detection, represents the company’s strategy to utilize advanced computational tools to enhance diagnostic precision.
In a statement, Rashid Ahmed Bux, president and CEO of BioMark, commented, “The acceptance of our work in Frontiers in Oncology is a pivotal moment for BioMark, as it provides third-party validation of the investments we have made in AI and machine learning over the past several years. At a time when the healthcare industry is increasingly looking for ‘proof of concept’ in AI applications, this publication confirms that our collaborative work with Harrisburg University meets the highest standards of scientific excellence. We have successfully demonstrated that integrating machine learning with metabolomics is not just a theoretical pursuit, but a validated methodology that provides deep insights into the metabolic complexities of lung cancer.”
